Active Biotech AB (ACTI) - Total Liabilities
Based on the latest financial reports, Active Biotech AB (ACTI) has total liabilities worth Skr12.50 Million SEK (≈ $1.35 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Active Biotech AB to track the company's year-over-year net asset growth rate.
Active Biotech AB - Total Liabilities Trend (2000–2024)
This chart illustrates how Active Biotech AB's total liabilities have evolved over time, based on quarterly financial data. See ACTI cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Active Biotech AB Competitors by Total Liabilities
The table below lists competitors of Active Biotech AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
|
USA | $855.00K |
|
NextEye Co. Ltd
KQ:137940
|
Korea | ₩40.27 Billion |
|
Exagen Inc
NASDAQ:XGN
|
USA | $37.52 Million |
|
Bhageria Industries Limited
NSE:BHAGERIA
|
India | Rs2.67 Billion |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
USA | $222.87 Million |
|
Aluko Co Ltd
KO:001780
|
Korea | ₩527.00 Billion |
|
VenueG Co. Ltd
KQ:019010
|
Korea | ₩277.35 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Active Biotech AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACTI stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.17 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.75 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Active Biotech AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Active Biotech AB (2000–2024)
The table below shows the annual total liabilities of Active Biotech AB from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr11.13 Million ≈ $1.20 Million |
-16.82% |
| 2023-12-31 | Skr13.38 Million ≈ $1.44 Million |
-18.88% |
| 2022-12-31 | Skr16.49 Million ≈ $1.78 Million |
+62.82% |
| 2021-12-31 | Skr10.13 Million ≈ $1.09 Million |
+0.88% |
| 2020-12-31 | Skr10.04 Million ≈ $1.08 Million |
-23.76% |
| 2019-12-31 | Skr13.17 Million ≈ $1.42 Million |
-93.86% |
| 2018-12-31 | Skr214.52 Million ≈ $23.09 Million |
-5.14% |
| 2017-12-31 | Skr226.14 Million ≈ $24.34 Million |
-1.82% |
| 2016-12-31 | Skr230.32 Million ≈ $24.79 Million |
-14.33% |
| 2015-12-31 | Skr268.84 Million ≈ $28.93 Million |
-15.25% |
| 2014-12-31 | Skr317.21 Million ≈ $34.14 Million |
-12.47% |
| 2013-12-31 | Skr362.40 Million ≈ $39.00 Million |
+1.56% |
| 2012-12-31 | Skr356.82 Million ≈ $38.40 Million |
+0.08% |
| 2011-12-31 | Skr356.53 Million ≈ $38.37 Million |
+10.95% |
| 2010-12-31 | Skr321.34 Million ≈ $34.58 Million |
+3.70% |
| 2009-12-31 | Skr309.86 Million ≈ $33.35 Million |
+0.17% |
| 2008-12-31 | Skr309.34 Million ≈ $33.29 Million |
+3.12% |
| 2007-12-31 | Skr299.97 Million ≈ $32.28 Million |
-25.39% |
| 2006-12-31 | Skr402.04 Million ≈ $43.27 Million |
+2.81% |
| 2005-12-31 | Skr391.05 Million ≈ $42.08 Million |
+159.68% |
| 2004-12-31 | Skr150.59 Million ≈ $16.21 Million |
+169.76% |
| 2003-12-31 | Skr55.82 Million ≈ $6.01 Million |
-36.01% |
| 2002-12-31 | Skr87.24 Million ≈ $9.39 Million |
+26.51% |
| 2001-12-31 | Skr68.96 Million ≈ $7.42 Million |
-69.07% |
| 2000-12-31 | Skr222.92 Million ≈ $23.99 Million |
-- |
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more